Leuprorelin Sandoz (Leuprorelin)

Leuprorelin mimics natural GnRH but remains bound to pituitary receptors longer, causing an initial surge followed by down‑regulation of LH and FSH release. The sustained suppression of these gonadotropins leads to markedly lower testosterone and estradiol levels, which reduces hormone‑driven tumor growth and other estrogen‑dependent conditions.

The dose of Leuprorelin Sandoz is individualized by the prescribing clinician based on the specific indication, patient weight, and treatment goals. Healthcare professionals determine the appropriate strength, frequency, and duration, and patients should follow the prescriber’s exact instructions.

Leuprorelin is classified as Pregnancy Category X, indicating it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as it may affect the infant’s hormonal balance. Women of childbearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and the necessary import documentation.

Leuprorelin belongs to the same class as goserelin and triptorelin, sharing the mechanism of pituitary down‑regulation. Differences lie mainly in formulation, dosing intervals, and manufacturer pricing. Clinical efficacy is comparable, but individual patient tolerance, convenience of injection schedule, and supply chain considerations may influence the choice of agent.

Leuprorelin Sandoz must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If temporary temperature excursions occur, discard the product to ensure potency and safety.

Leuprorelin Sandoz is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a qualified healthcare professional using aseptic technique. The exact injection site, volume, and frequency are determined by the prescriber according to the therapeutic indication.

Serious risks include cardiovascular events such as myocardial infarction, severe allergic reactions (anaphylaxis), significant bone loss leading to fractures, and profound depression or suicidal ideation. Patients should be monitored closely for these events, and any concerning symptoms should prompt immediate medical evaluation.

Leuprorelin is contraindicated in pregnant women, individuals with known hypersensitivity to leuprorelin or any excipients, and patients with severe uncontrolled cardiovascular disease. Caution is also advised for those with existing osteoporosis, severe depression, or active liver disease, and the drug should be avoided in these populations unless benefits clearly outweigh risks.